Inspiro seeks to partner with pharmaceutical companies active in the global respiratory market who require novel inhaled drug delivery designs to extend patent life of existing dry powdered medications or to bring new dry powdered formulations to market.
The major device categories of for pulmonary administration of drugs to treat airway diseases include: metered-dose inhalers (MDIs), dry powder inhalers (DPIs) and nebulizers. Despite the numerous aerosol delivery devices currently on the market, many are less than optimally effective in deposing the necessary medication. The optimal delivery device strives for the most efficient and effective deposition of aerosol medication and takes into account drug particle/droplet size; design of the delivery device; and the patient's ability to use and understand the device.
Unfortunately, MDIs require “hand-breathing coordination,” which often leads to less effective deposition of medication; DPIs rely on breath actuation for dose release and may require forceful inhalation; and with nebulizers treatment time is relatively long, set-up is cumbersome, and the apparatus is usually bulky and inconvenient.
The market requires an innovative aerosol delivery device that is convenient and easy to use; offers an effective deposition of medication; and is suitable for everybody including children, the elderly, and the seriously ill.
Inspiro’s unique DPI device is suitable for the treatment of pulmonary diseases such as asthma and chronic obstructive pulmonary disease (COPD).
According to the World Health Organization,
- An estimated 300 million people worldwide suffer from asthma, with 250,000 annual deaths attributed to the disease.
- COPD affects 210 million people worldwide and projected to be the third leading cause of death by 2020.